Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma

Elisa K. Liu, Varshini Vasudevaraja, Vladislav O. Sviderskiy, Yang Feng, Ivy Tran, Jonathan Serrano, Christine Cordova, Sylvia C. Kurz, John G. Golfinos, Erik P. Sulman, Daniel A. Orringer, Dimitris Placantonakis, Richard Possemato, Matija Snuderl

Research output: Contribution to journalArticlepeer-review


Background: Hyperglycemia has been associated with worse survival in glioblastoma. Attempts to lower glucose yielded mixed responses which could be due to molecularly distinct GBM subclasses. Methods: Clinical, laboratory, and molecular data on 89 IDH-wt GBMs profiled by clinical next-generation sequencing and treated with Stupp protocol were reviewed. IDH-wt GBMs were sub-classified into RTK I (Proneural), RTK II (Classical) and Mesenchymal subtypes using whole-genome DNA methylation. Average glucose was calculated by time-weighting glucose measurements between diagnosis and last follow-up. Results: Patients were stratified into three groups using average glucose: tertile one (<100 mg/dL), tertile two (100-115 mg/dL), and tertile three (>115 mg/dL). Comparison across glucose tertiles revealed no differences in performance status (KPS), dexamethasone dose, MGMT methylation, or methylation subclass. Overall survival (OS) was not affected by methylation subclass (P =. 9) but decreased with higher glucose (P =. 015). Higher glucose tertiles were associated with poorer OS among RTK I (P =. 08) and mesenchymal tumors (P =. 05), but not RTK II (P =. 99). After controlling for age, KPS, dexamethasone, and MGMT status, glucose remained significantly associated with OS (aHR = 5.2, P =. 02). Methylation clustering did not identify unique signatures associated with high or low glucose levels. Metabolomic analysis of 23 tumors showed minimal variation across metabolites without differences between molecular subclasses. Conclusion: Higher average glucose values were associated with poorer OS in RTKI and Mesenchymal IDH-wt GBM, but not RTKII. There were no discernible epigenetic or metabolomic differences between tumors in different glucose environments, suggesting a potential survival benefit to lowering systemic glucose in selected molecular subtypes.

Original languageEnglish (US)
Article numbervdac163
JournalNeuro-Oncology Advances
Issue number1
StatePublished - Jan 1 2022


  • glioblastoma
  • glucose
  • hyperglycemia
  • methylation
  • subclass

ASJC Scopus subject areas

  • Clinical Neurology
  • Oncology
  • Surgery


Dive into the research topics of 'Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma'. Together they form a unique fingerprint.

Cite this